BCL2 and lymphoma: Integrating anti-apoptotic molecule Bcl-2 into CAR design is a useful strategy for improving CAR-T cell proliferation in vitro and anti-tumor activity in vivo, which provides a potential approach for optimization of CAR-T cells against lymphoma in clinic.